Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells $415,013.94 in Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $96.47, for a total transaction of $415,013.94. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Kathleen Goin also recently made the following trade(s):

• On Wednesday, November 19th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The stock was sold at an average price of $86.23, for a total transaction of $370,961.46.

Palvella Therapeutics Price Performance

Shares of NASDAQ PVLA opened at $99.73 on Monday. The stock has a market capitalization of $1.18 billion, a P/E ratio of -37.92 and a beta of -0.20. The company has a 50-day moving average price of $85.80 and a 200-day moving average price of $57.64. Palvella Therapeutics, Inc. has a 1 year low of $11.17 and a 1 year high of $112.00.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). As a group, equities research analysts anticipate that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Archer Investment Corp bought a new stake in shares of Palvella Therapeutics in the 3rd quarter worth approximately $28,000. Russell Investments Group Ltd. purchased a new stake in Palvella Therapeutics in the third quarter worth $36,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Palvella Therapeutics in the second quarter worth $37,000. JPMorgan Chase & Co. raised its stake in shares of Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after buying an additional 3,242 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Palvella Therapeutics during the 2nd quarter valued at $85,000. 40.11% of the stock is owned by institutional investors.

Key Stores Impacting Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Oppenheimer raised its price target to $200 from $120, a strong signal from a sell‑side firm that can boost bullish interest. Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer
• Positive Sentiment: TD Cowen raised its price target to $133, adding further upward pressure on the stock via another institutional endorsement. TD Cowen Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $133.00
• Positive Sentiment: Market headlines note an analyst upgrade that coincided with a recent sharp move higher in PVLA shares, which likely amplified buying momentum. Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 6.6% After Analyst Upgrade
• Neutral Sentiment: HC Wainwright revised down near‑term EPS forecasts for FY2027–FY2029 (multiple cuts) but kept a “Buy” rating and a $200 price target — a mixed signal that tempers long‑term optimism with weaker near‑term profitability projections.
• Negative Sentiment: Lifesci Capital cut its FY2026 EPS estimate (worse expected losses), a negative revision that could weigh on sentiment if the company misses near‑term expectations.
• Negative Sentiment: COO Kathleen Goin sold 4,302 shares at an average price of $96.47 (SEC filing), a disclosure investors often view as a cautionary sign even if the sale may be for personal reasons. SEC filing

Analyst Ratings Changes

PVLA has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Palvella Therapeutics in a research report on Monday, December 15th. Craig Hallum began coverage on shares of Palvella Therapeutics in a research note on Thursday, December 4th. They issued a “buy” rating and a $175.00 target price for the company. Raymond James Financial reissued a “strong-buy” rating and set a $193.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. Truist Financial boosted their price target on shares of Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Finally, HC Wainwright set a $200.00 price objective on shares of Palvella Therapeutics and gave the company a “buy” rating in a research note on Monday, December 15th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $155.60.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.